Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now?

AstraZeneca PLC (AZN), a leading biopharmaceutical company, has been a subject of interest for investors due to its strong financial performance and innovative drug portfolio. However, the question remains: is AZN a cheap NASDAQ stock to invest in at the current moment? This article will analyze the company's valuation, dividend metrics, and market trends to provide a balanced perspective on this investment opportunity.

Firstly, let's examine AstraZeneca's valuation compared to its historical average and industry peers. As of November 2024, AZN is trading at a market capitalization of $195.50 billion and an enterprise value of $220.74 billion. Its trailing P/E ratio is 30.10, and the forward P/E ratio is 13.70. While the trailing P/E ratio suggests that AZN may be overvalued compared to its historical average of around 15-20, the forward P/E ratio indicates potential growth prospects. In comparison, AstraZeneca's industry peers have P/E ratios ranging from 10 to 20, with an average of around 15. Thus, AZN appears relatively expensive compared to its peers based on its trailing P/E ratio but may offer growth opportunities according to its forward P/E ratio.

AstraZeneca's dividend metrics are attractive, with a yield of 2.35% and a payout ratio of 35.78%. This yield is higher than the NASDAQ's average yield of approximately 1.5% and indicates a solid investment opportunity. The payout ratio of 35.78% suggests a sustainable dividend policy, as it is well below the historical average of around 50%. Compared to its competitors, such as Pfizer (PFE) with a yield of 2.8% and a payout ratio of 56%, and Merck & Co. (MRK) with a yield of 2.9% and a payout ratio of 48%, AstraZeneca's dividend metrics are competitive and suggest a strong investment case.



AstraZeneca's revenue and earnings growth are driven by its innovative drug portfolio, particularly in the areas of oncology, cardiovascular, renal, and metabolism. The company's strong performance is attributable to the success of its key products, such as Tagrisso, Imfinzi, Lynparza, and Calquence, which have shown significant growth in sales. AstraZeneca's pipeline of new drugs and its strategic partnerships also contribute to its revenue and earnings growth. However, the sustainability of this growth depends on factors such as the regulatory environment, competition, and the company's ability to maintain its competitive advantage in the market.

AstraZeneca's debt-to-equity ratio of 0.77 and interest coverage ratio of 10.12 indicate a strong balance sheet, with manageable debt levels and robust earnings to cover interest expenses. Compared to its peers, AstraZeneca's ratios suggest a lower risk profile, allowing it to maintain its dividend payments and reinvest in growth opportunities.

In conclusion, AstraZeneca PLC (AZN) offers an attractive dividend yield and a strong balance sheet. While its trailing P/E ratio suggests that it may be relatively expensive compared to its peers, the forward P/E ratio indicates potential growth prospects. AstraZeneca's innovative drug portfolio and strategic partnerships drive its revenue and earnings growth, but the sustainability of this growth depends on various market factors. Investors should carefully consider these aspects and monitor market trends to make informed decisions about investing in AZN.